Get the Stockscreener App
58.86
1.60%
-0.96
Biomarin Pharmaceutical Inc stock is traded at $58.86, with a volume of 1.02M.
It is down -1.60% in the last 24 hours and down -0.96% over the past month.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
See More
Previous Close:
$59.82
Open:
$59.82
24h Volume:
1.02M
Relative Volume:
0.63
Market Cap:
$11.90B
Revenue:
$2.75B
Net Income/Loss:
$322.29M
P/E Ratio:
35.25
EPS:
1.67
Net Cash Flow:
$300.88M
1W Performance:
-5.11%
1M Performance:
-0.96%
6M Performance:
-12.24%
1Y Performance:
-27.97%
1-Day Range:
$58.81
$60.66
1-Week Range:
$58.74
$62.83
52-Week Range:
$52.93
$94.85
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Name
Biomarin Pharmaceutical Inc
Sector
Industry
Phone
(415) 506-6700
Address
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
58.86 | 11.90B | 2.75B | 322.29M | 300.88M | 1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-24-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-30-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-20-24 | Upgrade | Bernstein | Mkt Perform → Outperform |
| May-17-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-24 | Initiated | Evercore ISI | Outperform |
| Nov-15-23 | Initiated | Wells Fargo | Overweight |
| Oct-23-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Sep-28-23 | Initiated | Raymond James | Mkt Perform |
| Sep-18-23 | Initiated | UBS | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| Jul-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Feb-22-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-21-23 | Initiated | Citigroup | Neutral |
| Jan-30-23 | Initiated | BMO Capital Markets | Market Perform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Oct-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| Apr-25-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-09-21 | Upgrade | Stifel | Hold → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-04-21 | Resumed | Guggenheim | Buy |
| Mar-01-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Aug-20-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-19-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-19-20 | Downgrade | Stifel | Buy → Hold |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-06-20 | Reiterated | Citigroup | Buy |
| Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-24-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-27-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-23-19 | Resumed | Citigroup | Buy |
| Apr-09-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-18 | Reiterated | Stifel | Buy |
| Aug-03-18 | Reiterated | Stifel | Buy |
View All
Biomarin Pharmaceutical Inc Stock (BMRN) Latest News
Shareholders Will Be Pleased With The Quality of BioMarin Pharmaceutical's (NASDAQ:BMRN) Earnings - Yahoo Finance
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock - Yahoo Finance
BioMarin Pharmaceutical Inc. (BMRN): Among Billionaire Paul Singer’s Stock Picks with Huge Upside Potential - Insider Monkey
10 Stocks That Will Make You Rich In 3 Years - Insider Monkey
BioMarin Pharmaceutical Inc. (BMRN): Among Stocks That Will Make You Rich In 3 Years - Insider Monkey
BioMarin outlines 2025 revenue growth with VOXZOGO expected to reach $950M - MSN
BlackRock, Inc. Reduces Stake in BioMarin Pharmaceutical Inc. - GuruFocus
Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock - Yahoo
10 Analysts Assess Biomarin Pharmaceutical: What You Need To Know - Benzinga
Goldman Sachs Adjusts Price Target for Biomarin Pharmaceutical ( - GuruFocus
Why BioMarin Pharmaceutical (BMRN) is a Top Momentum Stock for the Long-Term - Yahoo Finance
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2025 Earnings Call Transcript - Insider Monkey
Biomarin Pharmaceutical (BMRN) Price Target Lowered by Citigroup - GuruFocus
BioMarin Pharmaceuticals Reports Strong Q1 2025 Earnings - TipRanks
Biomarin Pharmaceutical (BMRN) Price Target Lowered by Citigroup | BMRN Stock News - GuruFocus
Cantor maintains BioMarin stock overweight with $90 target By Investing.com - Investing.com South Africa
BioMarin's First-Quarter Earnings & Sales Beat Estimates - Zacks Investment Research
BIOMARIN PHARMACEUTICAL INC SEC 10-Q Report - TradingView
Cantor maintains BioMarin stock overweight with $90 target - Investing.com
BioMarin Pharmaceutical Inc. to Host Earnings Call - ACCESS Newswire
BioMarin’s Strong Q1 2025 Performance and Growth Outlook - TipRanks
BioMarin Pharmaceutical Inc reports results for the quarter ended March 31Earnings Summary - TradingView
BioMarin (BMRN) Reports Strong Q1 2025 Growth and Strategic Adva - GuruFocus
Biomarin Pharma earnings beat by $0.43, revenue topped estimates - Investing.com India
BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Earnings call transcript: BioMarin beats Q1 2025 forecasts, stock rises after hours - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
BioMarin Pharmaceutical (BMRN) Beats Q1 Earnings and Revenue Estimates - Yahoo Finance
BioMarin Pharmaceutical (NASDAQ:BMRN) Beats Q1 Sales Targets - Yahoo Finance
BMRN Q1 Revenue Surpasses Expectations with Strong Product Deman - GuruFocus
BioMarin: Q1 Earnings Snapshot - News-Times
BioMarin Pharmaceutical Q1 Non-GAAP EPS, Revenue Rise - marketscreener.com
BioMarin Pharmaceutical Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:BMRN) - Seeking Alpha
Biomarin Pharmaceutical Inc. Q1 Profit Increases, Beats Estimates - Nasdaq
Earnings Flash (BMRN) Biomarin Pharmaceutical Reports Q1 Adjusted EPS $1.13, vs. FactSet Est of $0.80 - marketscreener.com
BioMarin Reports First Quarter 2025 Results and Reaffirms Full-year Guidance - PR Newswire
The Top 12 Companies Hiring in Biopharma Now - BioSpace
BioMarin Pharmaceutical Inc expected to post earnings of 71 cents a shareEarnings Preview - TradingView
BioMarin Pharmaceutical Inc. (BMRN): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside Potential - Insider Monkey
What To Expect From BioMarin Pharmaceutical’s (BMRN) Q1 Earnings - Barchart.com
Is BioMarin Pharmaceutical (NASDAQ:BMRN) A Risky Investment? - simplywall.st
20 Takeover Rumors Hedge Funds Are Buying - Insider Monkey
BioMarin Pharmaceutical Inc. (BMRN): Among Takeover Rumors Hedge Funds Are Buying - Yahoo Finance
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term - Yahoo
Implied Volatility Surging for BioMarin Stock Options - Yahoo Finance
Oppenheimer maintains BioMarin stock Outperform with $98 target By Investing.com - Investing.com Nigeria
Oppenheimer maintains BioMarin stock Outperform with $98 target - Investing.com
Joshua Grass, John Kelly, and Lauren Daniel Join 5AM Ventures - GlobeNewswire Inc.
Biomarin Pharmaceutical Inc Stock (BMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.84%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):